Spectral Medical (Edtxf) (TSE:EDT) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Spectral Medical Inc. has reported progress in the first quarter of 2024 with 106 patients enrolled in the Tigris trial, aiming for a target of 150 to advance towards FDA submission for its sepsis treatment. The company has also reinforced its collaboration with Baxter, extending their commercial partnership to ten years post-FDA approval. With recent financing, Spectral is poised to complete Tigris trial enrollment, bolstered by the addition of new trial sites and focused clinical support.
For further insights into TSE:EDT stock, check out TipRanks’ Stock Analysis page.